Latest Insights

How Digital Health Technologies are Reshaping Clinical Development

Despite rising trial costs and increasingly complex development timelines, one trend is clear: digital health technologies are rapidly moving from pilot programs to core components of global clinical trial strategy. …

Continue ›››

Eli Lilly Strikes Up to $1.1B Gene Editing Deal with German Startup

Eli Lilly has entered a collaboration with Seamless Therapeutics worth up to $1.12 billion to co-develop gene editing therapies targeting genetic forms of hearing loss. The agreement grants Lilly exclusive …

Continue ›››

This AI-Ready Single-Molecule Proteomics $1.6M Grant Targets Parkinson’s Alpha Synuclein

Washington- and California-based Nautilus Biotechnology is teaming up with Weill Cornell Medicine–Qatar and the Michael J. Fox Foundation (MJFF) for Parkinson’s Research on a new research program targeting alpha-synuclein, a protein …

Continue ›››

FDA Greenlights First Human Trial of Epigenetic ‘Rejuvenation’ Therapy for Vision Loss

The U.S. Food and Drug Administration has cleared Life Biosciences’ Investigational New Drug application for ER-100, allowing the Boston-based biotechnology company to begin a Phase 1 clinical trial in patients …

Continue ›››

This Company Claims World-First AI Models For Programmable Gene Insertion

That’s the headline from Basecamp Research this week, and if it holds up, it’s an important signal for genetic medicine field.

Continue ›››

Antheia Adds $24M in Series C Extension to Expand U.S. Biosynthetic Drug Manufacturing

Menlo Park–based Antheia has added $24 million in a second close of its Series C round, bringing its total raised over the past year to more than $175 million. The …

Continue ›››

In Another Major R&D Deal, Insilico Taps Chinese Pharma for AI-Designed Cardiometabolic Drugs

Insilico Medicine has signed a strategic collaboration with Chinese Qilu Pharmaceutical valued at nearly $120 million to co-develop small molecule therapies targeting cardiometabolic diseases. The partnership will leverage Insilico’s Pharma.AI …

Continue ›››

Neurotech Trends in 2025: When Use Cases Started Driving Design

Neurotechnology development in 2025 showed a shift from exploratory demonstration toward systems engineered around specific clinical and research uses. Across brain–computer interfaces, neuromodulation, diagnostics, and experimental neuroscience, design choices increasingly …

Continue ›››

How Digital Health Technologies are Reshaping Clinical Development

Eli Lilly Strikes Up to $1.1B Gene Editing Deal with German Startup

This AI-Ready Single-Molecule Proteomics $1.6M Grant Targets Parkinson’s Alpha Synuclein

FDA Greenlights First Human Trial of Epigenetic ‘Rejuvenation’ Therapy for Vision Loss

This Company Claims World-First AI Models For Programmable Gene Insertion

Antheia Adds $24M in Series C Extension to Expand U.S. Biosynthetic Drug Manufacturing

In Another Major R&D Deal, Insilico Taps Chinese Pharma for AI-Designed Cardiometabolic Drugs

Neurotech Trends in 2025: When Use Cases Started Driving Design

Insilico Medicine Launches AI Gym for LLMs and Secures FDA Clearance for AI-Designed NLRP3 Inhibitor

Tempus Launches Paige Predict, Following $81M Paige AI Acquisition

“ChatGPT for Doctors” Raises $250M Series D at $12B Valuation

BioAge to Begin Mid-2026 Trial of Oral NLRP3 Inhibitor in Diabetic Macular Edema